<span item_type="fundamental" item_id="618db84523105c4f266f1c7cb437ca28" counter_id="ST/US/BCTXW" env="prod"></span><span item_type="announcement" item_id="528068492008038273" env="prod"></span><p>EPS: As of FY2025 Q3, the actual value is USD -1.64.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Research, Development, and Clinical Trial Costs</strong>: For the three-month period ended April 30, 2025, total research, development, and clinical trial costs amounted to $4,810,196, compared to $7,657,632 for the same period in 2024. For the nine-month period ended April 30, 2025, these costs were $14,160,314, down from $22,772,344 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000164117225015265/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The net loss for the three-month period ended April 30, 2025, was $6,224,929, compared to a net income of $1,692,242 for the same period in 2024. For the nine-month period ended April 30, 2025, the net loss was $18,392,033, compared to $3,682,796 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000164117225015265/form10-q.htm"></span></li><li><strong>Operating Loss</strong>: The operating loss for the three-month period ended April 30, 2025, was $6,328,255, compared to $9,229,648 in 2024. For the nine-month period ended April 30, 2025, the operating loss was $18,650,530, compared to $27,562,122 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000164117225015265/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Net cash used in operating activities for the nine-month period ended April 30, 2025, was $20,038,075, compared to $20,090,398 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000164117225015265/form10-q.htm"></span></li><li><strong>Financing Activities</strong>: Cash gained from financing activities for the nine-month period ended April 30, 2025, was $31,891,239, compared to nil for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000164117225015265/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Change in Fair Value of Warrant Liability</strong>: For the three-month period ended April 30, 2025, the change in fair value of the warrant liability was $175,826, compared to $10,945,672 in 2024. For the nine-month period ended April 30, 2025, it was $366,024, compared to $23,660,003 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000164117225015265/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company is advancing its Bria-IMT™ targeted immunotherapy in a pivotal Phase 3 study in metastatic breast cancer, which is under Fast Track Designation by the U.S. FDA. Completion of this study could lead to full approval of Bria-IMT™ plus an immune checkpoint inhibitor.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000164117225015265/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: BriaCell is conducting a Phase <sup>1</sup>⁄<sub>2</sub> study to evaluate Bria-OTS™, a personalized next-generation immunotherapy, in metastatic breast cancer and other cancers. This study investigates Bria-OTS™ alone and in combination with an immune checkpoint inhibitor.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1610820/000164117225015265/form10-q.htm"></span></li></ul>

BRIACELL THERAPEUTICS CORP C/WTS 26/02/2026(TO PUR COM) | 10-Q: FY2025 Q3 EPS: USD -1.64